Skip to main content
. 2017 Feb 7;8(27):43782–43798. doi: 10.18632/oncotarget.15156

Figure 5. TAT-BMI-1 pretreatment of CB-CD34+ cells enhances hematopoietic engraftment in NOG mice.

Figure 5

(A) The percentage of total human leukocytes (CD45+), myeloid (CD33+) and B-lymphoid (CD19+) cells in peripheral blood of NOG mice transplanted with TAT-GFP or TAT-BMI-1-treated CD34+ cells was analysed by flow cytometry 7 and 12 weeks after the injection. (B) The percentage of total human leukocytes (CD45+), myeloid (CD11B+,CD33+) and B-lymphoid (CD19+, CD3+) cells in the bone marrow of NOG mice transplanted with TAT-GFP or TAT-BMI-1-treated CD34+ cells was analysed by flow cytometry 12 weeks after injection. (C) The percentage of total human CD45+ cells was analysed by flow cytometry in peripheral blood (weeks 9 and 14 post-transplant) and bone marrow (week 16 post-transplant) of NOG mice transplanted with bone marrow from the primary recipients shown in panel B.